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Résumé en
anglais
The assessment of minimal residual disease (MRD) in acute myeloblastic leukemia is
of growing interest as a prognostic marker of patients' outcome. Multiparameter flow
cytometry (MFC), tracking leukemia-associated immunophenotypic patterns, has
been shown in several studies to be a useful tool to investigate MRD. Here, we report
a multicenter prospective study which allowed to define a harmonized analysis
strategy, as well as the efficacy of MFC MRD to predict outcome. This study included
276 patients, in 10 different MFC centers, of whom 268 had at least 1 MRD check
point. The combination of a CD45, CD34, and CD33 backbone, with the addition of
CD117, CD13, CD7, and CD15 in 2 five-color tubes allowed to define each patient's
multiparameter immunophenotypic characteristics at diagnosis, according to a
Boolean combination of gates. The same individual diagnosis gating strategy was
then applied at each MRD time point for each patient. MRD levels were stratified
according to log by log thresholds, from 5 × 10 (the classical morphological threshold
to define remission) down to <5 × 10 . MRD was found to be constantly negative
(<5 × 10 ) for 148 patients. Survival analyses significantly associated MRD negativity
with a good prognosis and any positive value with poorer outcome. All P values were
<0.0001 both for disease-free and overall survival at the earliest time point (post-
induction, MRD1) as well as when considering all time points together. Finally, MRD
levels were independent of cytogenetics and allowed in fact to further stratify all
cytogenetics risk groups. In summary, this multicenter study demonstrates that a
simple combination of immunophenotypic markers successfully allows for the
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